The presence of an NRAS mutation correlates with shorter survival from the diagnosis of stage IV melanoma. The presence of either a BRAF or NRAS mutation is associated with an increased risk of CNS involvement at initial stage IV diagnosis. The gene discussed is NRAS; the disease is melanoma.